ACTRN12618000121268招募中不适用
A Phase 1, Placebo-Controlled, Double-Blind, Dose-Escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Dose of Getagozumab in Healthy Volunteers
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 32
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 60 Years（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
已完成
不适用
A Phase 1, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ISIS 325568 Administered to Healthy Volunteersdisorder with hyperglycemia10018424diabetes mellitusNL-OMON31095ISIS Pharmaceuticals56
已完成
不适用
A Phase 1, Double Blind, Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ISIS 388626 Administered to Healthy Volunteersdisorder with hyperglycemia10018424Diabetes MellitusNL-OMON35464ISIS Pharmaceuticals103
已完成
1 期
A Phase 1, Double-Blind, Randomized, Placebo-controlled, Single Ascending Dose Study of Flecainide Acetate Inhalation Solution to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy VolunteersRecent Onset Paroxsymal Atrial FibrillationCardiovascular - Other cardiovascular diseasesACTRN12616001156471InCarda Therapeutics Australia44
已完成
1 期
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of FlecIH-101 Versus Placebo in Healthy VolunteersCardiovascular - Other cardiovascular diseasesParoxysmal atrial fibrillationACTRN12618001239257InCarda Therapeutics Australia, Pty, Ltd22
已完成
1 期
A Phase 1 study to evaluate Safety, Tolerability and Pharmacokinetics of Ultramicronized-Palmitoylethanolamide (PEA) in Healthy Subjects.Chronic PainInflammationInflammatory and Immune System - Other inflammatory or immune system disordersACTRN12620000213943FSD Pharma Inc.48